Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
cSCC is one of the most common cancers in the U.S. and globally
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated